Search clinical trials for: VX15/2503

Total 83 results

Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Osteosarcoma | Refractory Osteosarcoma

United States
Vaccinex Inc.
PPD

Completed

Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors

Solid Tumors

United States
Vaccinex Inc.
PRA Health Sciences

Completed

Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS

Multiple Sclerosis

United States
Vaccinex Inc.
Huntington Study Group

Completed

A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi (SIGNAL-HD)

Huntington's Disease

United States, Canada
Emory University
Vaccinex Inc.

Recruiting

VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Vaccinex...

Completed

VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer

Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Colorectal Adenocarcinoma | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic... and other conditions

United States
Emory University
Bristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of... and other collaborators

Active, not recruiting

VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma

Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8

United States
Vaccinex Inc.
Merck KGaA, Darmstadt, Germany

Completed

VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer (CLASSICAL-Lung)

Carcinoma, Non-Small-Cell Lung

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); Vaccinex Inc.

Terminated

Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Vaccinex Inc.
Alzheimer's Association; Alzheimer's Drug Discovery Foundation

Active, not recruiting

SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD) (SIGNAL-AD)

Alzheimer Disease

United States
Vaccinex Inc.
Merck Sharp & Dohme LLC

Recruiting

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-B84)

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

United States
University of Alabama at Birmingham
National Cancer Institute (NCI); Ionis Pharmaceuticals, Inc.

Completed

ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas

Pancreatic Cancer

United States
University of Alabama at Birmingham
National Cancer Institute (NCI)

Terminated

ISIS 2503 in Treating Patients With Metastatic and/or Locally Recurrent Colorectal Cancer

Colorectal Cancer

United States
Istituti Clinici Scientifici Maugeri SpA

Active, not recruiting

Seizures and Traumatic Brain Injury Rehabilitation

Seizures | Traumatic Brain Injury

Italy
ProofPilot
Fisher Wallace

Active, not recruiting

Brain Stimulation & Generalized Anxiety Study

Generalized Anxiety Disorder | Anxiety | Generalized Anxiety

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy

Advanced Solid Tumor

United States
University Hospital Dubrava

Active, not recruiting

Registry of Hospitalized Patients in University Hospital Dubrava Respiratory Center (COVID-19)

Sepsis | Covid19 | Thrombosis | Bleeding | Inflammatory Response | Mechanical Ventilation Complication

Croatia
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Gemcitabine and ISIS 2503 in Treating Patients With Advanced or Metastatic Cancer of the Pancreas

Pancreatic Cancer

United States
Vertex Pharmaceuticals Incorporated

Terminated

Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

Cervical Spinal Cord Injury

United States, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibrosis Who Have an R117H-CFTR Mutation, Including Pediatric Patients

Cystic Fibrosis
Vertex Pharmaceuticals Incorporated

Completed

Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

Cystic Fibrosis

United States, France, United Kingdom, Germany, Belgium, Denmark, Canada, Australia, Sweden
Vertex Pharmaceuticals Incorporated

Completed

A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee

Osteoarthritis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

Cystic Fibrosis

Australia
Vertex Pharmaceuticals Incorporated

Terminated

A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation

Cystic Fibrosis

United States, Canada
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance

HIV-1 and Hepatitis C Co-Infection

United States
Parion Sciences
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United Kingdom, United States, France, Ireland
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation

Cystic Fibrosis

United States, Canada, Australia, Ireland, Germany, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)

Cystic Fibrosis

United States, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

Australia, United Kingdom
Vertex Pharmaceuticals Incorporated

Terminated

A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation

Cystic Fibrosis

United Kingdom, Canada, Australia
Vertex Pharmaceuticals Incorporated

Completed

Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation

Cystic Fibrosis

Netherlands
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation

Cystic Fibrosis

United States, Canada, United Kingdom, Australia, Ireland
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Canada, United Kingdom, Australia, Spain, Germany, Italy, Austria, Belgium, Denmark
Vertex Pharmaceuticals Incorporated

Completed

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

Cystic Fibrosis

United States, Canada
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Chloroquine for Reducing Immune Activation in HIV- Infected Individuals

HIV Infections

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Sevelamer for Reducing Endotoxemia and Immune Activation

HIV-1 Infection

United States
Kiniksa Pharmaceuticals, Ltd.

Completed

KPL-301 for Subjects With Giant Cell Arteritis

Giant Cell Arteritis

United States, Belgium, Croatia, Germany, Italy, Poland, Serbia, United Kingdom, Australia, Estonia, Ireland, Netherlands, New Zealand, Slovenia, Spain
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir

HIV-1 Infection

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression

HIV Infections

United States
Kiniksa Pharmaceuticals, Ltd.

Completed

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

Prurigo Nodularis | Pruritis

United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Italy, Korea, Republic of, Poland, Taiwan, United Kingdom
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study (LEAP-001)

Endometrial Neoplasms

China
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID); Pfizer

Completed

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

HIV-1 Infection

United States, Puerto Rico
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults

HIV Infections

United States, Puerto Rico
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Rifaximin as a Modulator of Microbial Translocation and Immune Activation

HIV-1 Infection

United States, Puerto Rico
Oscotec Inc.

Unknown

A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.

Rheumatoid Arthritis

United States, Czechia, Poland, Russian Federation, Ukraine
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART

HIV-1 Infection

United States, Puerto Rico
UCB BIOSCIENCES GmbH
Parexel

Completed

Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo (C-OPTIMISE)

Ankylosing Spondylitis | Axial Spondyloarthrithis

United States, Belgium, Bulgaria, Czechia, France, Germany, Hungary, Netherlands, Poland, Romania, Spain, Taiwan, Turkey, United Kingdom
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

HIV-1 Infection

United States, Puerto Rico
Noema Pharma AG

Recruiting

An Efficacy and Safety Study of Basimglurant in Patients With Trigeminal Neuralgia.

Trigeminal Neuralgia

United States, Italy, Spain, United Kingdom, Poland, Turkey, Germany, Denmark
Genzyme, a Sanofi Company

Active, not recruiting

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Thyroid Cancer

United States, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Hungary, India, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Romania, Russian Federation, Serbia, Spain, Sweden, Switz...

Search clinical trials for: VX15/2503

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations